PharmaVoice

Pharma Tech

Beijing unveils blueprint for biomedical dominance by 2030

Outlining a five-year biomedical plan, China wants to expand its global role beyond just pipeline innovation.

Express Pharma

Biocon receives EMA CHMP approval for Pertuzumab biosimilar

Biocon Biologics announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the granting of a marketing authorisation to its Pertuzumab biosimilar as 420 mg concentrate solution for infusion, under the brand name Pebrilzo, for the treatment of HER2-positive breast cancer across […] The post Biocon receives EMA CHMP approval for Pertuzumab biosimilar appeared first on Express Pharma.

Read Full Article

Pharma Tech

Telix to acquire ITM in deal worth up to $2.35bn

Telix Pharmaceuticals has agreed to acquire ITM Isotope Technologies Munich in a transaction valued at up to $2.35bn, combining Telix’s operations with ITM’s radioisotope production business and late-stage treatment candidate ITM-11.

Read Full Article

Pharma Tech

How DFE Pharma supports confident continuous manufacturing decisions

DFE Pharma supports confident continuous manufacturing decisions with CM-ready excipients, non-GMP testing and expert support.

Read Full Article

Express Pharma

Akums announces DCGI-approved triple therapy for H. pylori infection

Akums Drugs & Pharmaceuticals has announced the development of a DCGI-approved Clarithromycin + Vonoprazan + Amoxicillin Combikit for the treatment of Helicobacter pylori (H. pylori) infection in adults. The development is part of the company’s ongoing work in pharmaceutical formulation and reflects the growing focus within healthcare on treatment approaches that consider both therapeutic requirements […] The post Akums announces DCGI-approved triple therapy for H. pylori infection appeared first on Express Pharma.

Read Full Article

Featured promotional

Jeplus.in

Purchase All Medicines.Get 10% Offer

News

Latest stories

Pharma Tech

Sep 21, 2026, 2:36 PM

Beijing unveils blueprint for biomedical dominance by 2030

Outlining a five-year biomedical plan, China wants to expand its global role beyond just pipeline innovation.

Beijing unveils blueprint for biomedical dominance by 2030

Biocon receives EMA CHMP approval for Pertuzumab biosimilar

Telix to acquire ITM in deal worth up to $2.35bn

How DFE Pharma supports confident continuous manufacturing decisions

Akums announces DCGI-approved triple therapy for H. pylori infection

Featured promotional

Jeplus.in

Latest stories

Beijing unveils blueprint for biomedical dominance by 2030

ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO

Novo Nordisk aims to launch more than five blockbuster drugs by 2030, CEO says

Corcept Therapeutics Reports the CHMP Positive Opinion of Lifyorli (Relacorilant) to Treat Platinum-Resistant Ovarian Cancer

AstraZeneca Reports the CHMP Positive Opinion for Klygefa to Treat Generalised Myasthenia Gravis

Grünenthal to Acquire Bayer’s Stivarga for ~€375M

Latest industry coverage

Double-Wall Containment Gloves Market Forecast to 2035: Growth Accelerates on Pharma Cleanroom Demand - IndexBox

Teva Pharmaceutical Industries Ltd (TEVA) Stock Up 3.5% but GF V - GuruFocus

Pharmaceutical Companies Push Trump Administration to Protect China Deals - WSJ

Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020 - PR Newswire

Novo Nordisk and Anthropic Announce Collaboration to Advance Drug Discovery With Claude - BioBuzz

Cipher Pharmaceuticals Announces the Appointment of Rajiv De Silva to its Board of Directors - marketscreener.com

Cipher Pharmaceuticals Announces the Appointment of Rajiv De Silva to its Board of Directors - Yahoo Finance

StockWatch: Novo’s 2030 Strategy Underwhelms Investors at Capital Markets Day - genengnews.com

Novo Nordisk’s stock tumbles as doubts persist about Ozempic maker’s strategy - MarketWatch

Featured promotions

Jeplus.in